Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Insurance Restructuring or Co-pay Caps? Testing Nuanced Messages In Charged Pricing Debate

This article was originally published in RPM Report

Executive Summary

The drug pricing debate isn’t fun for anyone in the biopharma sector, but it isn’t likely to go away soon. A recent Center for American Progress event highlights the challenges of finding the right message in a sound-bite focused climate – but also the benefits of engaging directly with critics.

You may also be interested in...



Lilly, Anthem Singing Same Tune On Value-Based Pricing, Communication Policy

“Project Indy” offers a joint manufacturer/payor perspective on how to enable value based pricing. It also sounds like a potential proposal to CMS to volunteer for a pilot project.

The Campaign Against Drug Pricing: Candidates Can Only Hope Voters React As Strongly As Wall Street

Wall Street remains hypersensitive to threats from Washington or the campaign trail to take action to limit prescription drug pricing. But it is still hard to see why the threat is any greater because the Clinton campaign has a “plan” to address the issue.

New EU Filings

Omaveloxolone, Reata Pharmaceuticals’s orphan drug for treating patients with Friedreich’s ataxia, is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS079944

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel